Puma Biotechnology (PBYI) Long-Term Deferred Tax (2024 - 2026)
Puma Biotechnology's (PBYI) quarterly Long-Term Deferred Tax came in at $3.8 million in Q1 2026, down 45.87% YoY from $7.1 million in Q1 2025, and little changed on a QoQ basis from $3.8 million in Q4 2025.
Puma Biotechnology (PBYI) Long-Term Deferred Tax (2024 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 3 years of Long-Term Deferred Tax data on file, last reported at $3.8 million in Q1 2026.
- Quarterly Long-Term Deferred Tax fell 45.87% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (down 45.87% YoY) and the FY2025 annual result came in at $3.8 million, down 45.87% from the prior year.
- Long-Term Deferred Tax steadied at $3.8 million in Q1 2026, from $3.8 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $7.1 million in Q4 2024 to a low of $3.8 million in Q4 2025.
- A 3-year average of $6.0 million and a median of $7.1 million in 2024 frame the typical range for Long-Term Deferred Tax.
- The widest YoY moves for Long-Term Deferred Tax: up 45.87% in 2025, down 45.87% in 2025.
- Tracing PBYI's Long-Term Deferred Tax over 3 years: stood at $7.1 million in 2024, then slumped by 45.87% to $3.8 million in 2025, then changed by 0.0% to $3.8 million in 2026.
- The last three Long-Term Deferred Tax figures came in at $3.8 million (Q1 2026), $3.8 million (Q4 2025), and $7.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.83 Mn |
| Mar 31, 2026 | 3.83 Mn |
| Dec 31, 2025 | 3.83 Mn |
| Sep 30, 2025 | 7.08 Mn |
| Jun 30, 2025 | 7.08 Mn |
| Mar 31, 2025 | 7.08 Mn |
| Dec 31, 2024 | 7.08 Mn |